Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition

Ajay Aggarwal(King's College London), Jan van der Meulen(London School of Hygiene & Tropical Medicine), Malcolm D. Mason(Royal Marsden Hospital), Richard Sullivan(Precision Spine (United States)), Noel W. Clarke(The Christie NHS Foundation Trust), Susan C. Charman(MRC Biostatistics Unit), Daniel Lewis(The Huntington Library, Art Museum, and Botanical Gardens)
European Urology
July 29, 2017
10.1016/j.eururo.2017.07.013
Cited by 43

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|The Lancet Oncology|2020|1.9k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
The Lancet Commission on diagnostics: transforming access to diagnostics
|The Lancet|2021|442